Sumanta K. Pal, MD: Interpreting the Latest Results From the COSMIC-021 Study on Cabozantinib Plus Atezolizumab in Urothelial Carcinoma

Posted: Monday, June 13, 2022

Sumanta K. Pal, MD, of City of Hope National Medical Center, puts into perspective the findings on cabozantinib plus atezolizumab, and the encouraging clinical activity demonstrated in patients with inoperable locally advanced or metastatic urothelial carcinoma.